The CRO madness continues as Goldman Sachs-backed buyer group shells out $8.5B for Parexel
The Covid-19 pandemic has kicked the contract research field into high gear, with a particular focus on decentralized trials as the research tool of the future. With so much work — and cash — flying around, some deep-pocketed investors are signing big checks to get in on the game.
Count Goldman Sachs among them.
Goldman Sachs’ private equity branch and the EQT IX fund will pay $8.5 billion to acquire CRO Parexel as part of a buyout that continues a hot run of M&A in the booming field of contract research, the company confirmed Friday.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 124,400+ biopharma pros reading Endpoints daily — and it's free.